Abstract. Shikonin, a natural naphthoquinone isolated from a traditional Chinese medicinal herb, has been reported to promote tumor cell death. However, there are few reports concerning its effect on metastasis-related cell invasion and migration behavior. In the present study, we investigated the effect of shikonin on human breast cancer invasion and migration. We found that shikonin inhibited phorbol 12-myristate 13-acetate (PMA)-induced cell migration and invasion in MCF-7 breast cancer cells, which was correlated with modulation of matrix metalloproteinase-9 (MMP-9) through suppression of both expression and proteolytic and promoter activity. We also found that shikonin inhibited both MMP-9 expression and promoter activity in MDA-MB-231 cells with high metastatic potential. These results indicated that shikonin induces the suppression of migration and invasion through modulation of MMP-9 in human breast cancer cells. Therefore, shikonin may be a potential anticancer drug for human breast cancer therapy.

Introduction

Breast cancer ranks among the most common malignant tumors afflicting women worldwide (1). Cancer metastasis is the leading cause of mortality in patients with breast cancer; breast cancer survival rates fall from 90% for localized to 20% for metastatic disease. Therefore, controlling metastasis and invasion represents an important therapeutic strategy (2). Metastasis requires that invasive cells detach from localized tumors by degrading the extracellular matrix using proteases, including matrix metalloproteinases (MMPs); survive in the circulation as circulating tumor cells (CTCs); and colonize distant locations. Thus, understanding the molecular mechanisms underlying each of these steps is essential for targeting metastatic cells at an early stage and improving patient survival (3).

MMPs are a family of extracellular matrix (ECM)-degrading enzymes comprising 24 members. Based on their substrates, MMPs are divided into four subclasses: collagenase, gelatinase, stromelysin and membrane-associated (4). As a main ECM-degrading enzyme family, MMPs have essential roles in physiologic processes such as tissue development, remodeling and wound healing (5). However, they are also involved in certain tissue destructive diseases, such as atherosclerosis, inflammation, rheumatoid arthritis, and tumor invasion, metastasis and neoangiogenesis (6). Recent studies have shown that MMPs are important elements of the tumor microenvironment, regulating tumor progression, metastatic niche formation and inflammation in cancer (7). Among human MMPs, MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) are key enzymes in the degradation of type IV collagen, which is an important component of the ECM. MMP-2 and MMP-9 are the MMP members primarily associated with tumor migration, invasion and metastasis of various types of cancers (8). It has been shown that enhanced expression of MMP-9 is associated with the progression and invasion of tumors, whereas MMP-2 is usually expressed constitutively (9,10). Thus, researchers have focused on discovering inhibitors of MMP activity as a strategy for suppressing tumorigenesis and metastasis.

Shikonin is an active naphthoquinone compound and the main component of red pigment extracts from the Chinese medicinal herb, Lithospermum erythrorhizon Sieb et Zucc. Shikonin and its analogues can kill cancer cells through a number of mechanisms, including inhibition of topoisomerase-I (11), polo-like kinase 1 (PLK1) and protein tyrosine kinase (PTK) (12); regulation of phosphorylation-dependent activities of extracellular-regulated protein kinase (pERK), c-Jun N-terminal kinase (JNK) and protein kinase Ca (PKCa) (13); suppression of tumor necrosis factor receptor-associated protein 1 (TRAP1) expression (14); activation of caspases (15);
and inhibition of proteasome activity (16). In previous studies, shikonin and its derivatives were shown to exert anti-proliferative and pro-apoptotic effects against a number of tumor cells, including sarcoma 180 (S-180) ascites cells, gastric cancer, colon adenocarcinoma and oral cancer (17). A recent report also showed that shikonin activates the p53 and caspase-9 pathways (18) in human malignant melanoma A375-S2 cells. However, little is known concerning its anti-invasion effects in human breast cancer cell lines. In the present study, we investigated the anti-invasion effects of shikonin and explored the possible molecular mechanisms in breast cancer using the human breast cancer cell lines, MDA-MB-231 and MCF-7. We showed that shikonin inhibits the migration and invasion of breast cancer cells by suppressing AP-1 transcription factor-mediated MMP-9 expression.

Materials and methods

Materials and reagents. Shikonin was purchased from Sigma (St. Louis, MO, USA) and antibodies against MMP-2 and MMP-9 were purchased from Calbiochem (Boston, MA, USA). Antibodies against PCNA and p65 were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). MMP-9 ELISA kits were purchased from R&D Systems (Abingdon, UK).

Cell line and cell culture. Human breast cancer cell lines, MCF-7 and MDA-MB-231, were used in the present study. Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS).

Transwell invasion assays. The invasion of tumor cells was assessed in Transwell chambers. A Transwell membrane (8-µm pore size, 6.5-mm diameter; Corning Costar Corporation) was used. A Transwell membrane coated with Matrigel (100 µg/ml, 100 µl/well) was used for the invasion assay. Cells were seeded onto the upper wells in the presence of different concentrations of shikonin. The bottom chambers of the Transwell were filled with conditioned medium. After incubation for 24 h, cells were fixed, stained and counted under a light microscope.

In-gel zymography. The MMP activities were assayed as previously described (19). Briefly, 5x10^5 cells in a 6-well plate were seeded and maintained in serum-free medium for 16-24 h. The conditioned medium was separated on a sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel containing 1 mg/ml gelatin. The gel was washed with buffer 1 [Tris-HCl (pH 7.5) and 2.5% Triton X-100], incubated overnight in buffer II [150 mM NaCl, 5 mM CaCl_2, 50 mM Tris-HCl (pH 7.6)] at 37°C and stained with Coomassie blue. The clear bands indicate where MMPs degraded gelatin.

Cell migration assay. Migration was assessed by a wound healing assay. Cells were seeded at 2x10^4 MCF-7 and MDA-MB-231 cells/well. After scraping the cell monolayer with a sterile micropipette tip, the wells were washed with serum-free medium several times with different concentrations of shikonin. The first image of each scratch was acquired at time zero. At 24 h, each scratch was examined and captured at the same location and the healed area was measured.

Western blotting. Cells were washed twice with 1X PBS, and cell extracts were prepared using RIPA buffer (1X PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS containing an additional 100 ml of 10 mg/ml PMSF, and 1 Complete Mini Protease Inhibitor tablet). Lysate proteins were resolved by SDS-PAGE and transferred using nitrocellulose membranes (Whatman Protran BA83; 0.2 µm) The membranes were incubated with TBS buffer containing 0.1% Tween-20 and 5% skim milk, and then exposed to the desired primary antibody. After treatment with the proper secondary antibody, the immunoreactive bands were visualized using standard ECL (Pierce, Rockford, IL, USA) method.

Reverse transcription-PCR. In the reverse transcription-PCR (RT-PCR) analysis, total RNA was extracted from the treated cells. For reverse transcription reaction, cDNA was synthesized from 1 µg of total RNA using the High Capacity cDNA synthesis kit (Applied Biosystems). The PCR primers used were as follows: MMP-9 sense, 5’-TTTGGACGCCGACAAGAAGTGG-3’ and MMP-9 antisense, 5’-TCCATCTCTTGAGACAAATACA-3’; MMP-2 sense, 5’-CATTCGGCTTCCAGGACCAT-3’ and MMP-2 antisense, 5’-GCTCTTGATGGCCTCTGAGTCTCA-3’; GAPDH sense, 5’-GCCATGGTCACCAACATGGGAC-3’ and GAPDH antisense, 5’-CGATTTCGCCGCTCGGCCCTGG-3’. PCR products were analyzed by agarose gel electrophoresis and visualized by treatment with ethidium bromide.

Electrophoretic mobility shift assay (EMSA). The oligonucleotides were labeled with [γ-32P]ATP and incubated with nuclear extracts for 30 min by using the Gel Shift Assay kit (Promega Corp., Madison, WI, USA). The DNA-protein complexes were resolved on non-denaturing and non-reducing 6% acrylamide gels. The probes used for EMSA were as follows. Probe for AP-1, 5’-CGC TTG ACT ATG CAC CG GAA-3’.

Statistical analysis. The results are presented as mean ± SE, and statistical comparisons between groups were carried out using one-way ANOVA followed by the Student’s-t test. P<0.05 was considered to indicate a statistically significant result.

Results

Effects of shikonin on the migration and invasion of breast cancer cells. To investigate the effects of shikonin on human breast cancer cell migration and invasion, we treated MDA-MB-231 cells with different concentrations of shikonin (1-5 µM) and performed wound healing and Matrigel-based Transwell invasion assays. As shown in Fig. 1, shikonin significantly inhibited MDA-MB-231 cancer cell migration by ~80% and invasion by ~60%. Moreover, shikonin induced a concentration-dependent inhibition of PMA-induced migration and invasion of MCF-7 cells. MCF-7 cells treated with PMA presented a 1.5-fold increase in migration (Fig. 1A and B). However, treatment with 5 µM shikonin inhibited PMA-induced migration by ~70% in the MCF-7 cancer cell line (Fig. 1A and B). We next examined whether shikonin inhibits PMA-induced invasion in MCF-7 cells. PMA induced a 2-fold increase in the invasion of MCF-7 cells, while shikonin inhibited this invasion by ~60% at a 5 µM dose.
Figure 1. Effects of Shikonin on the migration and invasion of human breast cancer cells. (A) MDA-MB-231 and MCF-7 cells were ‘wounded’ by scratching with a pipette tip and then were incubated with or without 100 nM PMA and the indicated concentrations of shikonin. Representative images of wound healing were captured at the time of the scratch and 24 h later. Scale bars, 100 μm. (B) Cell migration into the wounded area was quantified as the fold ratio of wound healing (n=3). *P<0.05, **P<0.01 vs. vehicle alone-treated cells. #P<0.05, ##P<0.01 vs. PMA alone-treated cells. (C) Cells were treated with the indicated concentrations of shikonin, with or without 100 nM PMA, for 24 h, and invasion was determined by Transwell assays. Representative photomicrographs of membrane-associated cells were stained with eosin. (D) Cell invasion values were quantified (n=3). *P<0.05 vs. vehicle alone-treated cells. #P<0.05 vs. PMA alone-treated cells.
Shikonin inhibits MMP-9 expression and proteolytic activity. MMP-9 and MMP-2 are important ECM-degrading enzymes that are reported to be involved in cancer cell invasion and metastasis (20). On the basis of these observations and the foregoing data, we examined the effect of shikonin on the expression of both MMP-2 and MMP-9 in MDA-MB-231 cells; we also investigated PMA-induced MMP-9 expression in MCF-7 cells. Following treatment with shikonin, MMP-9 expression in the MDA-MB-231 cells gradually decreased over time at both the mRNA and protein levels (Fig. 2A and B). Shikonin also significantly inhibited PMA-induced expression of both MMP-9 mRNA and protein in the MCF-7 cells. However, neither PMA nor shikonin treatment affected MMP-2 mRNA or protein expression (Fig. 2A and B). We next examined MMP-2 and MMP-9 secretion and activity using gelatin zymography and enzyme-linked immunosorbent assays (ELISAs), respectively. MMP-9 secretion measured in the MDA-MB-231 cell-conditioned medium was significantly reduced by shikonin (Fig. 2C and D). Similarly, shikonin expression in the MDA-MB-231 cells gradually decreased over time at both the mRNA and protein levels (Fig. 2A and B). Shikonin also significantly inhibited PMA-induced expression of both MMP-9 mRNA and protein in the MCF-7 cells. However, neither PMA nor shikonin treatment affected MMP-2 mRNA or protein expression (Fig. 2A and B).
inhibited PMA-induced MMP-9 activity in the MCF-7 cells. These results indicate that shikonin is involved in the regulation of proteolytic activity as well as expression of MMP-9.

**Shikonin inhibits transcriptional activity of MMP-9 by suppressing AP-1 binding.** To explain the molecular mechanism underlying the inhibitory effects of shikonin on MMP-9 expression, we investigated the possible regulation of MMP-9 at the transcriptional level. The MMP-9 promoter contains two AP-1 binding sites and a nuclear factor (NF)-κB binding site, and it has been shown that NF-κB and AP-1 play critical roles in regulating basal and cytokine-induced MMP-9 expression in many cancer cell lines (19). Therefore, we examined whether shikonin inhibits MMP-9 expression through an effect on NF-κB or AP-1 binding sites in the MMP-9 promoter. Human breast cancer cells, MDA-MB-231 and MCF-7, were transiently transfected with the MCF-7 promoter construct. As shown in Fig. 3A, MMP-9 promoter activity was decreased in a dose-dependent manner following shikonin treatment in MDA-MB-231 cells. We also, confirmed that the MMP-9 promoter was activated up to ~10-fold in the PMA-treated MCF-7 cells. Shikonin showed a dose-dependent inhibition of PMA-induced MMP-9 promoter activity in the MCF-7 cells (Fig. 3D). Next, we examined whether shikonin affects the transcriptional activity of NF-κB and AP-1, critical modulators of MMP-9 activity. MDA-MB-231 cells were transiently transfected with AP-1 reporter vectors and then treatment of shikonin was carried out at different doses. As shown in Fig. 3C, AP-1 promoter activity was significantly reduced in the range of 1-5 mM of shikonin. In addition, MCF-7 cells were transiently transfected with reporter vectors containing tandem repeats of the AP-1 binding site to confirm the specificity of the shikonin-mediated inhibitory effect on AP-1. Treatment with PMA led to an ~7-fold increase in AP-1 promoter activity; notably, this stimulatory effect of PMA was significantly reduced by treatment with shikonin (Fig. 3F). However, NF-κB promoter activity exhibited significant change in the MDA-MB-231 and MCF-7 cells (Fig. 3B and E). These results suggest that shikonin inhibits MMP-9 activity through suppression of AP-1-mediated MMP-9 transcription in breast cancer cells.

**Shikonin decreases transcription factor binding to the AP-1 motif in the MMP-9 promoter region.** Next, we examined whether shikonin inhibits the transcriptional binding activity of AP-1 to its DNA motifs in MDA-MB-231 cells using electrophoretic gel mobility shift assay (EMSA). MDA-MB-231 cells were treated with different dose of shikonin for 24 h and nuclear extracts were prepared. As shown in Fig. 4A, shikonin significantly decreased AP-1 DNA binding activity. Subsequently, we examined whether the subunit of AP-1
transcription factor is regulated by shikonin. Expression levels of c-Fos and c-Jun, subunits of AP-1, were significantly reduced by shikonin treatment (Fig. 4C). Similar results were observed in MCF-7 cells. MCF-7 cells were pretreated with different concentrations of shikonin with 100 nM PMA. Then, nuclear extracts were prepared and analyzed for AP-1 DNA binding activities. As shown in Fig. 4B, shikonin significantly decreased PMA-induced AP-1 DNA binding ability. To determine which subunit of the AP-1 transcription factor is regulated by shikonin, we examined the expression levels of c-Fos and c-Jun following shikonin treatment. Our data showed that shikonin significantly reduced PMA-induced c-Jun and c-Fos expression but had little effect on the expression of p65 in the western blot assays (Fig. 4D). These results suggest that shikonin inhibits AP-1 transcription activity by suppressing its subunit expression.

Discussion

Members of the MMP family, in particular, MMP-9, are associated with regulation of cancer cell invasion and metastasis, the most insidious and life-threatening aspects of cancer (21,22). Therefore, the development of compounds capable of inhibiting MMP-9 could prove invaluable in the treatment of breast cancer patients. Shikonin has previously been shown to possess antiproliferative and pro-apoptotic activity in a number of tumor cells, but there is little information concerning its effects on tumor invasion (23). In the present study, we showed that shikonin effectively inhibited the migration and invasion of human breast cancer cells. We also found that shikonin inhibited the expression of MMP-9 in breast cancer cells, thereby reducing its proteolytic activity. These data suggest that shikonin suppresses the metastatic phenotype of human breast cancer cells via downregulation of MMP-9 expression. Previous studies have reported that the MMP-9 promoter contains a number of transcription factor-binding motifs, including those for NF-κB and AP-1 (24). The activity of the MMP-9 promoter is induced by AP-1 and/or NF-κB (25,26), which are two key transcription factors involved in the regulation of MMP-9 gene expression (24). Regulation of these transcription factors is also critically involved in the process of tumor metastasis. AP-1 is composed of members of the c-Jun and c-Fos families (27-29). Upon activation of AP-1, they associate to form a variety of homodimers and heterodimers that localize to the nucleus and regulate gene expression. Our results showed that shikonin decreased nuclear c-Fos
and c-Jun, without affecting p65. These data suggest that
the inhibitory effect of shikonin on AP-1 is responsible for
shikonin-induced inhibition of MMP-9 expression/activity,
and subsequent suppression of invasion.

In summary, we demonstrated that shikonin inhibits human
breast cancer cell migration and invasion by suppressing
MMP-9 activity by blocking the activation of AP-1 transcrip-
tion factors. Therefore, we conclude that shikonin is a potential
therapeutic agent that may be valuable in preventing the
metastasis of several types of human cancers, including breast
cancer.

Acknowledgements

This research was supported by the grant from Basic Science
Research Program through the National Research Foundation
of Korea grant funded by the Ministry of Education, Science,
and Technology of the Korea government (2011-0010430).

References

PMAMediated matrix metalloproteinase-9 gene activation
through the Ras/Raf/MEK/ERK- and Ap1-dependent mechani-
cancer cell invasion and metastasis by transcriptional activation
4. Yan and Boyd DD: Regulation of matrix metalloprotei-

6. Egeblad M and Werb Z: New functions for the matrix metallo-
proteinases in cancer progression. Nat Rev Cancer 2: 161-174,
2002.
7. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases:
regulators of the tumor microenvironment. Cell 141: 52-67,
2010.
8. Chambers AF and Matrisian LM: Changing views of the role
of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:
of matrix-metalloproteinase-9 in human breast cancer: a potential
favourable indicator in node-negative patients. Br J Cancer 84:
metalloproteinases in tumor invasion: role for cell migration.
11. Bailly C: Topoisomerase I poisons and suppressors as anticancer
induces apoptosis in human leukemia cells by inhibiting the
activity of a polo-like kinase 1 (PLK1). Oncogene 22: 1012-1023,
2003.
synthesized shikonin derivative, 2-hyim-DMNQ-S-33. Cancer
 necrosis factor receptor-associated protein 1 (TRAP1) in
apoptosis induced by β-hydroxyisovalerylshikonin. J Biol Chem
15. Yoon Y, Kim YO, Lim NY, Jeon WK and Sung HJ: Shikonin, an
ingredient of Lithospermum erythrorhizon induced apoptosis in
HL60 human promyelocytic leukemia cell line. Planta Med 65:
activity via proteasome inhibition and cell death induction
17. Gaddipati JP, Mani H, Shefali, et al: Inhibition of growth and
regulation of IGFs and VEGF in human prostate cancer cell
lines by shikonin analogue 93/637 (SA). Anticancer Res 20:
18. Wu Z, Wu L, Li L, Tashiro S, Onodera S and Ikejima T:
p53-mediated cell cycle arrest and apoptosis induced by shikonin
via a caspase-9-dependent mechanism in human malignant
effect of caffeic acid and caffeic acid phenol ester on hepato-
carcinoma cells: complete regression of hepatoma growth and
20. Hu B, Thirtamara-Rayamae K, Sim H and Viapiano MS:
Fibulin-3 is uniquely upregulated in malignant gliomas and
promotes tumor cell motility and Invasion. Mol Cancer Res 7:
1756-1770, 2009.
expression in human gastric cancer and induces MMP2 and
MMP9 expression in MKN-28 cells. Dig Dis Sci 53: 163-168,
2008.
invasion and metastasis of gastric cancer. Mol Cancer Res 5:
23. Min R, Sun Z, Min Y, Wenhui D, Wenjun Y and Chenping Z:
Shikonin inhibits tumor invasion via down-regulation of NF-kB-
mediated MMP-9 expression in human ACC-M cells. Oral Dis
binding activity and phosphatidylinositol 3-kinase pathway by
nobiletin, a polymethoxy flavonoid, results in augmentation of
tissue inhibitor of metalloproteinases-1 production and suppres-
sion of production of matrix metalloproteinases-1 and -9 in
human fibrosarcoma HT-1080 cells. Cancer Res 62: 1025-1029,
2002.
25. Gurn R, Lengyl E, Juarez I, et al: Stimulation of 92-kDa gela-
tinase B promoter activity by ras is mitogen-activated protein
kinase kinase 1-independent and requires multiple transcription
factors binding sites including closely spaced PEA3ets and AP-1
26. Yokoo T and Kitamura M: Dual regulation of IL-1β-mediated
matrix metalloproteinase-9 expression in mesangial cells by
27. Matthews CP, Colburn NH and Young MR: AP-1 a target for
28. Milde-Langosch K: The Fos family of transcription factors
29. Ozanne BW, Spence HJ, McGarry LC and Hennigan RF:
Transcription factors control invasion: AP-1 the first among